Cancer Vaccines Market

Global Cancer Vaccines Market was worth of USD 4.93 Billion in 2020 and it is expected to reach USD 12.64 Billion by the end of 2027 with a CAGR of 9.8% during the Forecast Period.

Global Cancer Vaccines Market: Global Size, Trends, Competitive, Historical & Forecast Analysis To 2021-2027, Increasing number of cancer patient, rising geriatric population and investment by the key payers and government initiative towards the development of cancer vaccine are anticipated to drive the growth of global cancer vaccine market

Scope of Global Cancer Vaccines Market Report-

Cancer is caused due to the growth of abnormal cell and accumulation of mutation genes in the different parts of body. Few types of cancer cannot be treated with conventional means such as radiation, chemotherapy and other, but can be controlled by using cancer vaccine. A Cancer Vaccine is a vaccine that prevents development of cancer or used in the treatment of existing cancer. Some vaccine is therapeutic while some of them are autologous. One approach for cancer vaccine is to separate protein from cancer cell and immune with those in human body as an antigen and another approach is to use oncolytic virus which was also used in the drug talimogene laherparepvec.

Cancer vaccine is used to target the tumor specific antigen which is different from their self-protein. The advantages of cancer vaccines is low toxicity, exquisite specificity and there potential for treatment due to its immunologic memory. Dr. William Coley attempted the first vaccine that stimulates the immune system to improve cancer patient situation by intratumoral injections of inactivated serratia marcescens & streptococcus pyogenes in 1891. Also, in 1981 hepatitis B vaccine was the first vaccine on liver cancer to get FDA approved to prevent from cancer which is known as the prophylactic vaccine. 

COVID-19 pandemic has shown the negative impact on the global cancer vaccines market due to the shortage of the production and supply all over the world. Cancer vaccine manufacturing and its distributers has been affected as most of them focused on the corona virus vaccine. Thus, the shortage of the raw material, labor unavailability and broken supply chain, including the shutdown in many countries has also affected the market growth. 

Global Cancer Vaccines Market Segmentation: -

Global cancer vaccines market is segmented on the basis of type, application technology, and region and country level. Based on the type the global cancer vaccines market is classified into therapeutic cancer vaccines, preventive cancer vaccines and others. Based on the application the global cancer vaccines market is classified into prostate cancer, cervical cancer and others. Based on the technology the global cancer vaccines market is classified into whole-cell cancer vaccine, DNA cancer vaccine, recombinant cancer vaccine and others.

By Cancer Vaccines Type

• Prophylactic Vaccines
• Therapeutic Vaccines

By Technology

• Peptide-based Vaccines
• DNA-based Vaccines
• RNA-based Vaccines
• Viral Vector-based Vaccines
• Whole Cell-based Vaccines

By Route of Administration

• Intramuscular
• Subcutaneous
• Intradermal

By Cancer Indications

• Cervical Cancer
• Prostate Cancer
• Lung Cancer
• Colorectal Cancer
• Breast Cancer
• Others

By End-Users

• Hospitals
• Clinics
• Research Institutes
• Pharmaceutical & Biotechnology Companies

Cancer Vaccine Companies

Some major key players for global cancer vaccines market report cover prominent players like

• Amgen
• AstraZeneca
• Bavarian Nordic
• Bristol Myers Squibb (BMS)
• Dendreon Pharmaceuticals
• GlaxoSmithKline plc (GSK)
• Gritstone Oncology
• ImmunoCellular Therapeutics
• Inovio Pharmaceuticals
• MaxCyte
• Merck & Co., Inc. (MSD)
• Oxford BioMedica
• Sanofi
• Takeda Pharmaceutical Company
• Vaxil Bio
• Others

Cleveland clinic launches its first preventive breast cancer vaccine study.

October 26th, 2021:  The breast cancer vaccine is developed by the Cleveland clinic immunologist Vincent Tuohy. It is a clinical trial to determine the dose of vaccine in patient with non- metastatic triple negative breast cancer vaccine which is the most lethal form of disease. This study has shown that a single dose of vaccine could prevent breast tumors from occurring and obstruct the growth of the existing cancer. About 15 to 20% of women diagnosed with the breast cancer have found to be in triple negative breast cancer. Around 70% to 80% of the tumors that occur in women with BRCA1 genes mutation are triple negative breast cancer. This vaccine will be preferred to prevent mastectomies for the women who decided to undergo voluntary bilateral mastectomy due to the high risk of developing cancer again. This is the phase 1trial with the Anixa Biosciences partnering with Cleveland to be most safe & effective in the early stage of cancer. This vaccine strategy will also be applied to the ovarian and endometrial cancer later.

Increasing number of cancer patients, rising geriatric population and investment by the key payers and government initiative towards the development of cancer vaccines are anticipated to drive the growth of the global cancer vaccine market.

One of the major factors that drive the market is increasing number of cancer patient. According to the cancer.gov, around 18 million new cancer patients found and almost 9.5 million deaths were confirmed from cancer in the year 2020 world-wide. Another factor that drives the market is the rising geriatric population. The cancer rates are highest in countries whose population has the high expectance, standard of living and educational level.  According to the American cancer society, almost 1.9 million new cases of cancer found in the US with the confirmed death cases are 608,570 in 2021. Also, the investment done in the cancer research and for advanced treatment the US NIH is the largest investor of about 7.3 billion dollar in 2018. 

However, hectic process, high cost & stringent rules and regulation for developing the cancer vaccine also the huge  time span require for manufacturing of vaccine will hamper the growth of the global cancer vaccines market. Additionally, rising number of cancer patient will give new opportunities to the key players including the advanced research and development to provide more reliable and advanced treatments over the forecast period. 

North America is set to maintain its Dominance in Global Cancer Vaccines Market.

North America is witnessing the growth due to the high prevalence of cancer patient & highly developed healthcare infrastructure in North America. The National Cancer Institute (NCI) supports the advanced cancer research across the nation which also includes the funding. According to the NCI, the death rate has been declined which means the cancer survivors in US has increased by 7 million to 15 million and is expected to rise about 26 million by 2040. NCI has the highest budget around 6.9 billion dollar in 2020, per year received funds is more than 5 billion dollar. Additionally, rising prevalence of cancer patients is the other factor that drives the market growth. The common cancer is lung, breast, colon, thyroid cancer and many more. According to the National Cancer Institute, 18, 06,590 new cases of cancer are diagnosed in U.S. and around 606,520 people will die. Moreover, new cases are found in 442 per 100,000 men and women per year in North America.

Asia Pacific is the second largest market in global cancer vaccines market. Some factors that drives the market in Asia pacific region is the technological advancement, rising government plans to prevent cancer and huge population. Most of the technologies used in the cancer treatment are antigen cancer vaccine, dendritic cancer vaccine and others.  In recent years the treatment for the cancer is increasing due to the technological advancement. Scientist from the national center for Nano science & technology in China, they were able to develop the mRNA vaccine to treat cancer including the emergence of nanotech-driven therapies as well as immunotherapy. 

According to the U.S food and drug administration had approved almost 47 immunotherapies that will cover almost major types of cancer. Another factor that drives the global cancer vaccines market is government plans and initiative taken by them. National cancer control planning provides different strategies for countries to decrease their cancer burden & risk factors in the context of their health systems and populations. According to the science direct, cancer patient is rising in Southeast Asia and Pacific that combined the increased cases from 942000 to 1.55 million by 2030 and death cases are 5,88,000 to 1.02 million over a period of time.

The regions covered in this global cancer vaccines market report are North America, Europe, Asia-Pacific and Rest of the World. On the basis of country level, the market is sub divided into U.S., Mexico, Canada, U.K., France, Germany, Italy, China, Japan, India, South East Asia, Middle East Asia (UAE, Saudi Arabia, Egypt) GCC, Africa, etc.

On Special Requirement cancer vaccines market Report is also available for below Regions and Country:

North America

• U.S.
• Canada

Europe

• Germany
• France
• U.K.
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Switzerland
• Belgium
• Rest of Europe

Asia-Pacific

• South Korea
• Japan
• China
• India
• Australia
• Philippines
• Singapore
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Colombia
• Brazil
• Argentina
• Peru
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Report Analysis	Details
Historical data	2015 - 2020
Forecast Period	2021 - 2027
Market Size in 2020:	USD 4.93 Billion
Base year considered	2020
Forecast Period CAGR %:	9.8%
Market Size Expected in 2027:	USD 12.64 Billion
Tables, Charts & Figures:	175
Pages	200
Cancer Vaccine Companies	Amgen, AstraZeneca, Bavarian Nordic, Bristol Myers Squibb (BMS), Dendreon Pharmaceuticals, GlaxoSmithKline plc (GSK), Gritstone Oncology, ImmunoCellular Therapeutics, Inovio Pharmaceuticals, MaxCyte, Merck & Co., Inc. (MSD), Oxford BioMedica, Sanofi, Takeda Pharmaceutical Company, Vaxil Bio, Others
Segments Covered	By Type, By Application, By Technology
Regional Analysis	North America, U.S., Mexico, Canada, Europe, UK, France, Germany, Italy, Asia Pacific, China, Japan, India, Southeast Asia, South America, Brazil, Argentina, Columbia, The Middle East and Africa, GCC, Africa, Rest of the Middle East and Africa

Key Benefits for Global Cancer Vaccine Market Report–

• Global Cancer Vaccine Market report covers in-depth historical and forecasts analysis.
• Global Cancer Vaccine Market research report provides detailed information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Cancer Vaccine Companies Market Opportunities, Competitive Analysis, Regional and Country Level.
• Global Cancer Vaccine Market report helps to identify opportunities in the marketplace.
• Global Cancer Vaccine Market report covers extensive analysis of emerging trends and competitive landscape.